New Delhi: lenmark Pharmaceuticals Ltd on Thursday said it has received approval from the US health regulator for its generic version of fluticasone propionate nasal spray indicated for treatment of rhinitis. The approval by the US Food and Drug Administration (USFDA) is for fluticasone propionate nasal spray of strength 0.05 mg/spray, Glenmark Pharmaceuticals said in a regulatory filing. Glenmark's fluticasone propionate nasal spray is bioequivalent and therapeutically equivalent to the reference listed drug, Flonase nasal spray, 0.05 mg/spray of Haleon US Holdings LLC, it added.